Provided by Tiger Trade Technology Pte. Ltd.

MannKind

4.15
-0.1100-2.58%
Post-market: 4.12-0.0300-0.72%19:30 EDT
Volume:3.20M
Turnover:13.59M
Market Cap:1.33B
PE:-29.64
High:4.36
Open:4.28
Low:4.11
Close:4.26
52wk High:6.51
52wk Low:2.23
Shares:321.54M
Float Shares:309.97M
Volume Ratio:0.82
T/O Rate:1.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1400
EPS(LYR):0.0200
ROE:32.74%
ROA:0.79%
PB:-19.86
PE(LYR):207.50

Loading ...

Mannkind Corp Shares up 3.4% as FDA Approves Drug-device Combo for Fluid Buildup

THOMSON REUTERS
·
Jul 24

U.S. Stocks on the Move-tenet Healthcare, Intel, Verizon

Reuters
·
Jul 24

MannKind Agrees to $50 Million Private Stock Sale

MT Newswires Live
·
Jul 24

Mannkind Climbs as FDA Approves Drug-device Combo for Fluid Buildup

Reuters
·
Jul 24

MannKind's Furoscix ReadyFlow Injection Approved by US FDA

MT Newswires Live
·
Jul 24

Mannkind Corp Shares up 5.4% Premarket After FDA Approves Co's Single-use Autoinjector to Treat Fluid Buildup

THOMSON REUTERS
·
Jul 24

Mannkind Prices USD 50 Million Private Placement at USD 3.89 Per Share

Reuters
·
Jul 24

Mannkind Announces $50 Million Private Placement

THOMSON REUTERS
·
Jul 24

MannKind Announces $50 Million Private Placement

GlobeNewswire
·
Jul 24

Mannkind Corp - Furoscix Readyflow Expected to be Available in U.S. by End of August 2026

THOMSON REUTERS
·
Jul 24

Mannkind Announces FDA Approval of Furoscix Readyflow™, the First and Only Autoinjector Delivering Iv-equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease

THOMSON REUTERS
·
Jul 24

MannKind nearing ‘underappreciated catalyst,’ says H.C. Wainwright

TIPRANKS
·
Jul 23

MannKind (MNKD) Stock Stays Cheap On Its 28% YTD Slump

Simply Wall St.
·
Jul 19

Mannkind Director Steven B. Binder Disposes of USD 214,089 Common Shares

Reuters
·
Jul 18

MannKind (MNKD) Secures Pediatric Afrezza Grant, Is The Stock Still Cheap?

Simply Wall St.
·
Jun 26

MannKind Awarded Breakthrough T1d Grant to Support Advancement of Inhale-1St Pediatric Trial of Afrezza® in Youth With Newly-Diagnosed T1d

THOMSON REUTERS
·
Jun 23

MannKind wins Breakthrough T1D grant for INHALE-1ST pediatric Afrezza trial

Reuters
·
Jun 23

Should Afrezza Pediatric Approval And New Data Shift MannKind’s (MNKD) Technosphere Platform Investment Narrative?

Simply Wall St.
·
Jun 09

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

GlobeNewswire
·
Jun 06

MannKind Completes Patient Randomization in Phase 1b Idiopathic Pulmonary Fibrosis Study

MT Newswires Live
·
Jun 03